Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AnaptysBio Inc. | Rosnilimab (ANB030) - (RENOIR) | Rheumatoid arthritis | Phase 2b | Data Released | Intravenous | Immunology: Anti-TNF |
| AnaptysBio Inc. | Imsidolimab (ANB019) - (HARP) | Hidradenitis Suppurativa | Phase 2 | Trial Completed | Intravenous | Immunology: Anti-TNF |
| AnaptysBio Inc. | Imsidolimab (ANB019) - (EMERGE) | EGFRi-Mediated Skin Toxicity | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Anavex Life Sciences Corp. | ANAVEX 3-71 | Frontotemporal dementia | Phase 2 | Trial Planned | Oral | Neurology |
| Anavex Life Sciences Corp. | ANAVEX 3-71 (AF710B) | Schizophrenia | Phase 2 | Data Released | Oral | Psychiatric |
| Anavex Life Sciences Corp. | ANAVEX 2-73-PDD-001 | Parkinson’s Disease Dementia (PDD) | Phase 2 | Data Released | Oral | Neurology |
| Anavex Life Sciences Corp. | ANAVEX 2-73 - (U.S. RS-001) | Rett syndrome | Phase 2 | Data Released | Oral | Genetic Disorder |
| Anavex Life Sciences Corp. | Blarcamesine (ANAVEX2-73-AD-004) - (ATTENTION-AD) | Mild to moderate Alzheimer’s disease | Phase 2/3 | Data Released | Oral | Neurology |
